Shares of Adeptus Health Inc. (NYSE:ADPT) have received an average rating of “Buy” from the ten brokerages that are presently covering the firm. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $84.00.
Several brokerages have recently commented on ADPT. Jefferies Group set a $77.00 price objective on shares of Adeptus Health and gave the company a “buy” rating in a research report on Thursday, September 8th. JMP Securities decreased their price objective on shares of Adeptus Health from $94.00 to $92.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 31st. Goldman Sachs Group Inc. set a $80.00 price objective on shares of Adeptus Health and gave the company a “buy” rating in a research report on Thursday, September 8th. Finally, Zacks Investment Research downgraded shares of Adeptus Health from a “buy” rating to a “strong sell” rating in a report on Wednesday, July 13th.
Several hedge funds have recently bought and sold shares of ADPT. Texas Permanent School Fund increased its stake in Adeptus Health by 94.0% in the first quarter. Texas Permanent School Fund now owns 9,584 shares of the company’s stock worth $532,000 after buying an additional 4,645 shares during the period. Prudential Financial Inc. increased its stake in Adeptus Health by 60.8% in the first quarter. Prudential Financial Inc. now owns 125,932 shares of the company’s stock worth $6,995,000 after buying an additional 47,632 shares during the period. Franklin Resources Inc. increased its stake in Adeptus Health by 10.0% in the first quarter. Franklin Resources Inc. now owns 700,061 shares of the company’s stock worth $38,881,000 after buying an additional 63,912 shares during the period. BlackRock Fund Advisors increased its stake in Adeptus Health by 10.2% in the first quarter. BlackRock Fund Advisors now owns 671,316 shares of the company’s stock worth $37,285,000 after buying an additional 62,193 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Adeptus Health by 11.1% in the first quarter. JPMorgan Chase & Co. now owns 31,405 shares of the company’s stock worth $1,744,000 after buying an additional 3,130 shares during the period.
Adeptus Health (NYSE:ADPT) opened at 40.97 on Thursday. The stock has a market capitalization of $669.86 million, a price-to-earnings ratio of 6.24 and a beta of 0.96. Adeptus Health has a 12 month low of $35.33 and a 12 month high of $90.71. The company has a 50-day moving average of $41.19 and a 200 day moving average of $52.02.
Adeptus Health (NYSE:ADPT) last issued its quarterly earnings results on Thursday, July 21st. The company reported $0.48 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.51 by $0.03. The business had revenue of $100.20 million for the quarter, compared to analysts’ expectations of $93.92 million. Adeptus Health had a return on equity of 14.74% and a net margin of 22.99%. The company’s revenue was up 36.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.44 EPS. On average, equities research analysts anticipate that Adeptus Health will post $2.46 earnings per share for the current fiscal year.
About Adeptus Health
Adeptus Health Inc is a patient-centered healthcare company. The Company is engaged in providing emergency medical care through a network of independent freestanding emergency rooms in the United States and partnerships with various healthcare systems. The Company has approximately 80 freestanding facilities and over two licensed general hospitals.
Receive News & Ratings for Adeptus Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adeptus Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.